February 12, 2010 – Page 2 – The Stem Cell Foundation

The Long-term Survival of a Patient With Pancreatic Cancer With Metastases to the Liver After Treatment With the Intravenous a – Lipoic Acid/Low-Dose Naltrexone Protocol

Post author:2by2host
Post published:February 12, 2010
Post category:Articles Cancer

The authors describe the long-term survival of a patient with pancreatic cancer without any toxic adverse effects. The treatment regimen includes the intravenous -lipoic acid and low-dose naltrexone (ALA-N) protocol…

Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease

Post author:2by2host
Post published:February 12, 2010
Post category:Articles

The objective of this study was to evaluate the safety, tolerability, and preliminary efficacy of intravenous glutathione in Parkinson's disease (PD) patients. This was a randomized, placebo-controlled, double-blind, pilot trial…

In vitro and in vivo neuroprotection by γ-glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson’s disease

Post author:2by2host
Post published:February 12, 2010
Post category:Articles

Abstract Glutathione is an abundant intracellular thiol antioxidant whose levels are reduced both in Parkinson's disease itself and in a widely used animal model of the disorder, systemic MPTP administration.…

Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: Relevance to Parkinson’s disease

Post author:2by2host
Post published:February 12, 2010
Post category:Articles

Abstract Parkinson's disease (PD) is associated with loss of total glutathione (GSH) which may contribute to progressive cell death. Peripheral GSH administration has been used clinically with reported benefits. Despite…